EVgo Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EVgo Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $54.59M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $22.21M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.05M | Mar 24, 2022 |
| FY2021 | Jan 15, 2020 | $1.53M | Mar 24, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $384.09M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $256.83M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $160.95M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $54.59M | Mar 6, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.78M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $29.37M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $9.71M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($5.65M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($6.83M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($9.60M) | Mar 24, 2022 |
| FY2021 | Jan 15, 2020 | $553.0K | Mar 24, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.57M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($44.33M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($42.43M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($27.58M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($5.91M) | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | ($14.30M) | May 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.66M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($131.57M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($153.41M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($149.50M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($89.83M) | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | ($1.01M) | May 3, 2021 |
| FY2021 | Jan 15, 2020 | ($763.0K) | Mar 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.20M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $11.60M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $5.70M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $4.80M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $2.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.20M | Mar 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.73M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($7.26M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($37.06M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($58.79M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($29.60M) | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | ($547.6K) | May 3, 2021 |
| FY2021 | Jan 15, 2020 | ($344.0K) | Mar 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $116.71M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $94.79M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $158.90M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $200.25M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $65.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.34M | Mar 24, 2022 |
| FY2021 | Jan 15, 2020 | $166.0K | Mar 24, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $964.83M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $803.76M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $806.61M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $729.72M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $746.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $182.14M | Mar 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $578.89M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $360.03M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $266.24M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $212.60M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $158.40M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $92.65M | Mar 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($116.90M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($256.11M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | ($160.59M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | ($358.10M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | ($1.36B) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $89.49M | Mar 30, 2023 |
| FY2020 | Aug 3, 2020 | $0 | May 3, 2021 |
| FY2021 | Jan 16, 2020 | $131.03M | Mar 24, 2022 |
| FY2021 | Jan 15, 2020 | $13.99M | Mar 24, 2022 |
| FY2021 | Dec 31, 2019 | $14.39M | Mar 24, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.05M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $31.05M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $31.05M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $31.05M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $31.05M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $22.11M | Mar 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($124.69M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($256.14M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($248.55M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($375.66M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($1.36B) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($47.79M) | Mar 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.00M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $117.27M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $208.67M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $245.72M | Mar 6, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $206.46M | Mar 9, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jul 1, 2021 | 264,537 | Mar 30, 2023 |